The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients. 

Radspherin, developed by biotechnology company Oncoinvent, is a receptor-independent alpha radiation therapy that destroys residual micrometastases using a single, highly localised dose of alpha radiation.  

The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumour and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs. 

The newly granted patent covers a key technical development which optimises Radspherin’s performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin in China is expanded in scope and duration, with a term extending to 2041.  

“We are very pleased to obtain this additional patent in China for Radspherin,” said Oystein Soug, Chief Executive Officer at Oncoinvent.  

“As we continue to advance clinical development, it is essential that our innovation is backed by a strong and durable global intellectual property position.” 

The post Radspherin receives patent protection in China  appeared first on Drug Discovery World (DDW).